

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Huntington disease | D006816 | Orphanet_399 | G10 | 1 | 4 | 2 | — | — | 7 |
| Amyotrophic lateral sclerosis | D000690 | EFO_0000253 | G12.21 | — | 1 | 1 | — | 1 | 2 |
| Motor neuron disease | D016472 | EFO_0003782 | G12.2 | — | 1 | 1 | — | 1 | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | 1 | — | — | — | 1 |
| Dyskinesias | D020820 | — | G24 | — | 1 | — | — | — | 1 |
| Drug common name | Pridopidine |
| INN | pridopidine |
| Description | Pridopidine (also known as PL-101) is an orally administrated small molecule investigational drug. Pridopidine is a selective and potent Sigma-1 Receptor agonist. It is being developed by Prilenia Therapeutics and is currently in late-stage clinical development for Huntington's disease (HD) and amyotrophic lateral sclerosis (ALS).
|
| Classification | Small molecule |
| Drug class | dopamine D2 receptor modulator |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | CCCN1CCC(c2cccc(S(C)(=O)=O)c2)CC1 |
| PDB | — |
| CAS-ID | 346688-38-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL596802 |
| ChEBI ID | — |
| PubChem CID | 9795739 |
| DrugBank | DB11947 |
| UNII ID | HD4TW8S2VK (ChemIDplus, GSRS) |
